NOV 17, 202666 MINS READ
Creatine phosphate (phosphocreatine, PCr) is a high-energy phosphate compound with the molecular formula C₄H₁₀N₃O₅P and a molecular weight of approximately 211.11 g/mol. The molecule consists of a creatine backbone (N-methylguanidino acetic acid) esterified at the guanidino nitrogen with a phosphate group. This phosphorylation confers unique chemical properties critical for energy buffering in excitable tissues. The phosphate moiety exhibits a pKa around 4.5, rendering the compound negatively charged at physiological pH and highly polar, which directly impacts chromatographic retention and ionization efficiency in mass spectrometry workflows 23.
The structural instability of the N-P bond under acidic conditions and during high-energy ionization processes presents a fundamental challenge in mass spectrometric analysis. Neutral loss of the phosphate group (loss of 80 Da corresponding to HPO₃) is frequently observed in collision-induced dissociation (CID) experiments, complicating quantitative analysis and requiring optimized ionization parameters to preserve the intact molecular ion 4. Understanding these structural vulnerabilities is essential for method development, as they dictate the choice of ionization mode, matrix composition, and fragmentation strategies employed in both MALDI-TOF and ESI-MS platforms.
In biological systems, creatine phosphate exists in equilibrium with creatine, adenosine triphosphate (ATP), and adenosine diphosphate (ADP) via the creatine kinase (CK) reaction: PCr + ADP ⇌ Creatine + ATP. This reversible reaction is central to cellular energy homeostasis, particularly in muscle and neural tissues where rapid ATP regeneration is required. The ability to accurately quantify creatine phosphate alongside its metabolic precursors (guanidinoacetate) and degradation product (creatinine) provides comprehensive insight into energy metabolism status and is clinically relevant for diagnosing creatine deficiency syndromes and monitoring ischemic injury 16.
Effective sample preparation is paramount for achieving reliable quantitation of creatine phosphate and related metabolites in biological matrices such as serum, plasma, urine, whole blood, and saliva 1. The primary objectives are to extract target analytes, remove interfering matrix components (proteins, lipids, salts), and concentrate analytes to levels compatible with instrumental detection limits.
High-performance liquid chromatography (HPLC) serves as the predominant purification technique prior to mass spectrometric detection 1. Reversed-phase chromatography using C18 columns is commonly employed, although the high polarity of creatine phosphate often necessitates hydrophilic interaction liquid chromatography (HILIC) to achieve adequate retention and separation from isobaric interferences. Mobile phase optimization typically involves volatile buffers (ammonium formate, ammonium acetate at 5–20 mM) compatible with electrospray ionization, with pH adjusted to 3.0–4.5 to enhance protonation of the guanidino group while minimizing in-source phosphate loss. Gradient elution programs spanning 5–15 minutes enable baseline separation of guanidinoacetate (GAA), creatine, creatine phosphate, and creatinine, with retention times highly dependent on column chemistry and organic modifier composition (acetonitrile vs. methanol) 1.
Solid phase extraction (SPE) provides an orthogonal or complementary purification strategy, particularly for urine samples with high salt content 1. Mixed-mode cation exchange (MCX) cartridges selectively retain protonated guanidino compounds under acidic loading conditions (pH 2–3), allowing salts and neutral interferences to be washed away before elution with ammonia-methanol solutions. Weak cation exchange (WCX) resins offer milder retention mechanisms suitable for labile phosphate esters. SPE workflows reduce ion suppression effects in ESI sources by 60–80% compared to direct injection, thereby improving sensitivity and reproducibility. Automated 96-well SPE platforms enable high-throughput processing of clinical cohorts, with recovery rates for creatine phosphate typically exceeding 85% when protocols are optimized 1.
For serum and plasma samples, protein precipitation using organic solvents (acetonitrile, methanol) or acids (trichloroacetic acid, perchloric acid) is a rapid initial step to remove macromolecular interferences 6. Trichloroacetic acid (10% w/v final concentration) effectively precipitates proteins while stabilizing phosphate esters against enzymatic hydrolysis by endogenous phosphatases. Following centrifugation (10,000–15,000 × g, 10 minutes, 4°C), supernatants are neutralized and subjected to SPE or direct LC-MS injection. Care must be taken to avoid excessive acidification, which can catalyze non-enzymatic dephosphorylation of creatine phosphate, leading to underestimation of true concentrations 26.
Electrospray ionization in positive mode is the preferred ionization technique for creatine phosphate mass spectrometry due to efficient protonation of the guanidino functional group 1. Under optimized source conditions (capillary voltage 3.0–4.5 kV, desolvation temperature 350–450°C, cone voltage 20–40 V), creatine phosphate generates predominantly [M+H]⁺ ions at m/z 212. The presence of the phosphate group, however, introduces competing ionization pathways, including formation of [M+Na]⁺ and [M+K]⁺ adducts (m/z 234 and 250, respectively) when alkali metal contamination is present in mobile phases or glassware. Rigorous control of mobile phase purity and use of metal-free chromatography systems are essential to maximize [M+H]⁺ ion abundance and minimize adduct formation, which dilutes analyte signal across multiple ion species 1.
Negative mode ESI can be employed to detect the deprotonated phosphate group ([M-H]⁻ at m/z 210), offering complementary selectivity and reduced matrix interference from non-phosphorylated metabolites. However, negative mode sensitivity for creatine phosphate is generally 3- to 5-fold lower than positive mode due to less favorable gas-phase basicity of the phosphate anion compared to protonation of the guanidino nitrogen. Polarity switching or parallel positive/negative acquisition modes enable simultaneous monitoring of both ionization pathways within a single chromatographic run, enhancing method robustness 1.
MALDI-TOF-MS offers rapid, high-throughput analysis of phosphorylated metabolites but faces significant challenges related to phosphate group lability under laser irradiation 45. Conventional matrices such as 2,5-dihydroxybenzoic acid (DHB) and α-cyano-4-hydroxycinnamic acid (CHCA) often induce extensive neutral loss of HPO₃ (80 Da) or H₃PO₄ (98 Da), resulting in predominant detection of dephosphorylated creatine ions (m/z 132) rather than intact creatine phosphate molecular ions (m/z 212). This fragmentation severely compromises quantitative accuracy and necessitates alternative matrix formulations.
Recent advances employ ionic liquid matrices composed of 3-aminoquinoline (3-AQ) cations paired with p-coumaric acid anions in molar ratios of 5:1 to 20:1 4. These liquid matrices provide a "soft" ionization environment that suppresses in-source fragmentation, achieving 10- to 10,000-fold sensitivity improvements for phosphorylated peptides and small molecules compared to DHB. For creatine phosphate, 3-AQ/p-coumaric acid matrices enable detection of intact [M+H]⁺ ions with minimal dephosphorylation artifacts, with limits of detection approaching 50 pmol when combined with on-target enrichment strategies 4. Addition of ammonium phosphate (10–50 mM) as a matrix additive further stabilizes the phosphate ester by providing a buffering environment and competing for protonation sites that would otherwise promote P-N bond cleavage 4.
Integration of magnetic affinity nanoparticles directly onto MALDI sample targets enables selective enrichment of phosphorylated metabolites prior to matrix application and laser desorption 5. Nanoparticles functionalized with metal oxide surfaces (TiO₂, ZrO₂, Fe₃O₄) or immobilized metal affinity chromatography (IMAC) ligands selectively bind phosphate groups via Lewis acid-base interactions. The workflow involves: (1) physical adsorption of magnetic nanoparticles onto the MALDI target under an external magnetic field; (2) sample loading and incubation (5–15 minutes) to capture creatine phosphate; (3) washing to remove non-phosphorylated interferences and salts; (4) removal of the magnetic field and addition of ionic liquid matrix for co-crystallization; and (5) MALDI-TOF-MS analysis 5. This on-target enrichment approach eliminates sample transfer steps, reduces losses, and enables parallel processing of multiple samples, with enrichment factors of 50- to 200-fold reported for phosphorylated peptides and applicable to small molecule phosphates 5.
Accurate quantitation of creatine phosphate requires incorporation of isotopically labeled internal standards to correct for matrix effects, ionization variability, and losses during sample preparation 1. Stable isotope-labeled creatine phosphate analogs, such as [¹³C₂,¹⁵N]-creatine phosphate or deuterated variants ([D₃]-creatine phosphate), are synthesized or commercially sourced and added to samples at the earliest possible stage (ideally during initial extraction). These internal standards co-elute with endogenous analytes and exhibit nearly identical ionization efficiency, enabling ratiometric quantitation that compensates for run-to-run variability. Typical internal standard concentrations range from 0.5 to 5 mg/L, selected to bracket expected endogenous levels in the biological matrix of interest 1.
For multi-analyte panels encompassing guanidinoacetate, creatine, creatine phosphate, and creatinine, a cocktail of isotopically labeled standards is employed, with each standard matched to its corresponding analyte. This approach ensures that matrix effects specific to each compound's retention time window are accurately corrected. Isotope dilution mass spectrometry (IDMS) using these labeled standards represents the gold standard for clinical and research applications, achieving inter-assay coefficients of variation (CV) below 5% and intra-assay CVs below 3% 1.
State-of-the-art LC-ESI-MS/MS methods for creatine phosphate achieve limits of quantitation (LOQ) at or below 1 mg/L in urine, with optimized protocols reaching 0.8 mg/L or lower 1. These LOQ values are determined as the lowest concentration at which the analyte can be quantified with acceptable precision (CV ≤ 20%) and accuracy (80–120% recovery). For serum and plasma, where endogenous creatine phosphate concentrations are typically lower (0.5–2 mg/L in healthy individuals), LOQs of 0.1–0.5 mg/L are necessary to capture physiological and pathological variations. Achieving these sensitivity thresholds requires optimization of injection volumes (10–50 µL), chromatographic peak focusing, and MS/MS transition selection to maximize signal-to-noise ratios 1.
Multiple reaction monitoring (MRM) or selected reaction monitoring (SRM) modes on triple quadrupole mass spectrometers provide the highest sensitivity and selectivity. For creatine phosphate, the primary MRM transition monitors the precursor ion [M+H]⁺ at m/z 212 and the product ion corresponding to loss of phosphoric acid (m/z 132, representing protonated creatine after neutral loss of H₃PO₄). Secondary transitions (e.g., m/z 212 → 90, corresponding to further fragmentation to the guanidino moiety) serve as qualifiers to confirm analyte identity and exclude isobaric interferences 1.
Calibration curves are constructed using matrix-matched standards to account for ion suppression or enhancement effects inherent to biological samples. For urine analysis, pooled blank urine is spiked with known concentrations of creatine phosphate (and other analytes) spanning the expected physiological range (e.g., 0.5–50 mg/L), along with fixed concentrations of isotopically labeled internal standards. Linear or quadratic regression models (weighted 1/x or 1/x²) are fitted to the analyte/internal standard peak area ratios versus nominal concentrations, with correlation coefficients (r²) typically exceeding 0.995 across the calibration range 1.
For serum and plasma, surrogate matrix approaches using bovine serum albumin solutions or charcoal-stripped serum may be employed when authentic blank matrices are unavailable due to ubiquitous presence of endogenous creatine phosphate. Standard addition methods, where known amounts of analyte are spiked into patient samples, provide an alternative calibration strategy that inherently corrects for matrix effects but are labor-intensive and less suitable for high-throughput applications 1.
Traditional enzymatic assays for creatine phosphate leverage the creatine kinase (CK) reaction in reverse to generate ATP from ADP and creatine phosphate, with subsequent ATP quantitation via coupled enzyme systems 6. In a typical protocol, serum or tissue extract is incubated with excess ADP, magnesium ions (Mg²⁺, 5–10 mM), and creatine kinase in a buffered solution (pH 9.0, Tris-HCl) at 37°C for 30 minutes. The reaction proceeds as: PCr + ADP + H⁺ → Creatine + ATP. The ATP generated is then quantified using hexokinase and glucose-6-phosphate dehydrogenase in a coupled reaction that produces NADH, which is measured spectrophotometrically at 340 nm 6.
Addition of sulfhydryl compounds such as glutathione, cysteine, or 2-mercaptoethanol (1–5 mM) to the reaction mixture is critical for maintaining CK enzyme activity by preventing oxidation of catalytic cysteine residues 6. These reducing agents enhance assay sensitivity and reproducibility, enabling detection of CK activity as low as 10 Units/mL serum. Following the incubation period, the reaction is terminated by addition of cold trichloroacetic acid (5–10% w/v final concentration), which precipitates proteins and stabilizes reaction products. The creatine phosphate formed (or consumed, depending on reaction direction) is then hydrolyzed under acidic conditions (1 N HCl, 100°C, 10 minutes) to release inorganic phosphate, which is quantified colorimetrically using the Fiske and Subbarow molybdate method 6.
The Fiske and Subbarow method involves formation of a phosphomolybdate
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| Quest Diagnostics Investments LLC | Clinical diagnostics for creatine deficiency syndromes, metabolic disorder screening in urine, serum, plasma, whole blood and saliva samples requiring sensitive detection of energy metabolism biomarkers. | Mass Spectrometry Assay for Creatine Metabolites | Achieves limit of quantitation below 1 mg/L for creatine, creatinine and guanidinoacetate in urine using LC-ESI-MS with isotopically labeled internal standards, enabling high precision quantitation with CV below 5%. |
| Shimadzu Corporation | High-sensitivity analysis of phosphorylated peptides and metabolites including creatine phosphate in proteomics research, enabling detection of labile phosphate esters without fragmentation artifacts. | MALDI-TOF Mass Spectrometry with Ionic Liquid Matrix | Utilizes 3-aminoquinoline/p-coumaric acid ionic liquid matrix achieving 10- to 10,000-fold sensitivity improvement compared to conventional DHB matrix, suppressing phosphate group desorption during ionization for intact molecular ion detection. |
| Institute of Radiation Medicine Academy of Military Medical Sciences | Large-scale phosphoproteomics analysis requiring rapid, sensitive detection of phosphorylated metabolites and peptides with minimal sample handling in biomedical research applications. | Magnetic Nanoparticle-Based MALDI Target Enrichment System | Enables on-target enrichment of phosphorylated peptides using magnetic affinity nanoparticles with 50- to 200-fold enrichment factor, eliminating sample transfer losses and enabling parallel high-throughput processing on MALDI targets. |
| Sigma Chemical Company | Clinical biochemistry laboratories for creatine kinase activity measurement in serum samples, cardiac and muscle injury diagnostics, and energy metabolism assessment in tissue extracts. | Creatine Phosphokinase Enzymatic Assay Kit | Incorporates sulfhydryl compounds (glutathione, cysteine, 2-mercaptoethanol) to maintain enzyme activity, enabling detection of CPK activity as low as 10 Units/mL serum with enhanced sensitivity and reproducibility at pH 9.0. |